Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor

Merck continues to diversify its cancer efforts as the clock ticks down on Keytruda’s patent, picking up rights to a preclinical oncology asset in a deal that could exceed $2 billion.